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http:WHAT THIS PAPER ADDS
Long-term follow up of chimney and periscope grafts for the treatment of pararenal and thoraco-abdominal
aortic aneurysm is presented. This approach using off the shelf devices has been increasingly reported in
recent years and with good results even in emergent settings. This risk factor analysis showed that inadequate
branch graft length and chimney and periscope use in small and diseased target arteries contribute to late
failure of this technique.Objective: The aim was to report on chimney and periscope grafts (CPGs) and their mid- and longer-term
outcomes when they are used to preserve reno-visceral artery (RVA) perfusion in endovascular repair of
pararenal (PRAAs) or thoraco-abdominal aortic aneurysm (TAAAs). In addition, factors associated with CPG failure
are presented. Limited data exist on the outcomes of CPGs, and mid- and long-term results are generally not
reported.
Methods: This was a prospective study in a cohort of 100 patients with PRAA (69) or TAAA (31). A total of 224
(mean 2.24 per patient) RVAs were preserved with 136 (61%) chimney and 88 (39%) periscope grafts. CPGs were
constructed mainly using self expandable stent grafts. Patients were followed by clinical examination, CTA (82%),
and/or duplex (18%). Data were collected until February 2015.
Results: CPG immediate technical success was 99% (222/224 branches). Mean follow up was 29 months (range
0e65; SD 17); 59% patients were followed > 2 years, 30% > 3 years, and 16% > 4 years. Post-operatively, CPG
occlusion was observed early (30 days) in three (1.3%) branches and during follow up in 10 (4.5%). At 36 and 48
months, the estimated primary patency was 93% and 93%. After corrective percutaneous (10) or surgical (3) re-
interventions, the estimated secondary patency was 96% and 96%. Thirty day mortality was 2%; at 36 and 48
months the estimated patient survival was 79%. Signiﬁcant shrinkage (72 [SD 23] vs. 62 [SD 24] mm; p < .001)
was observed, with a substantial reduction (>5 mm) in 55 patients, and sac enlargement in four. Incomplete
aneurysm sac sealing was treated successfully by a secondary intervention in 15 patients.
Conclusions: Self expandable CPGs have proved to be a highly successful and durable treatment for RVA
preservation up to 5 years. Incomplete CPG expansion, inadequate length, and CPG use in small and diseased
target arteries were risk factors for occlusion. These mid- and longer-term results support CPG use to treat PRAAs
or TAAAs in patients unﬁt for open surgery or fenestrated/branched stent grafts.
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Endovascular treatment of pararenal abdominal aortic an-
eurysms (PAAAs) and/or thoraco-abdominal aortic aneu-
rysms (TAAAs) is usually performed using fenestrated or
branched stent grafts (B/FEVAR).1 However, because of
anatomical limitations, device non-availability, and time
consuming customization, a signiﬁcant number of patients
are excluded from B/FEVAR.2 To overcome these limitations,
Table 1. Demographics, comorbidities, and operative details.
Patients 100
Female 21
Mean age 73  9
Hypertension 89
Diabetes 16
Lipid disorders 43
COPD 57
CAD 57
ASA class III/IV 62
class V 27
PAD 42
Hostile Chest/Abdomen 60
Mean GFR at baseline 54  13
GFR<60 46
ESRF 12
Dialysis 5
Pre-operative aneurysm
maximal transverse
diameter (mm)
Mean, Median,
Range
71.76  23,
65, 38e185
Aortic aneurysm type Pararenal 69
Suprarenal 25
Thoraco-abdominal 31
Crawford I 7
Crawford II 4
Crawford III 3
Crawford IV 9
Arch to visceral 8
Operation Elective 73
Non-elective 27
Symptomatic 15
Ruptured 12
Number of CPG 1 21
2 47
3 19
4 13
Main aortic stent graft Diameter (mm) 33  5
Excluder and TAGa 55
Endurant and Talentb 27
Evitac 17
Zenithd 1
In hospital stay (days) Mean 10  10
Intensive care unit
stay (days)
Mean 2  4
Median 0
Range 0e24
Note. Comorbidities were deﬁned according to the Ad Hoc
Committee for Standardized Reporting Practices in Vascular
Surgery of the Society for Vascular Surgery and the American
Association for Vascular Surgery; Juxtarenale, suprarenale und
Abschnitt-IV-Aneurysmen classiﬁcation; the Rutherford
classiﬁcation; and the National Kidney Foundation. COPD ¼
chronic obstructive pulmonary disease; GFR ¼ glomerular ﬁltration
2
Risk factors for failure of chimney and periscope 665parallel graft techniques using a combination of off the shelf
devices have been developed to ﬁt most of such complex
cases.3 Unfortunately, until now data published on chimney
and periscope grafts (CPGs) have been limited, especially
with regard to long-term results. In order to add supportive
data on the value of this technique, mid- and longer-term
outcomes of over 4 years of CPGs used in a single center
over an 8 year experience are reported. This series includes
100 consecutive patients treated by CPG techniques in an
intention to treat protocol, with standardized implantation
methods and follow up protocols.
METHODS AND PATIENTS
This was a single center retrospective analysis of prospec-
tively gathered data from 100 patients deemed unsuitable
for conventional surgery and treated from January 2008 to
August 2013 with at least one renal or visceral chimney or
periscope graft. A vascular board including a cardiovascular
surgeon and interventional radiologist selected patients.
Brieﬂy, patients with low surgical risk (good anatomy for
clamping and grafting; young with unrestricted organ
function, especially normal heart, lung and renal function)
were treated by open surgery.4 Patients presenting high risk
for conventional surgery were treated by hybrid repair
techniques (approximately 70e80% of all open repairs), and
patients at high surgical risk for open surgery and/or unﬁt
for fenestrated endovascular devices were treated endo-
vascularly with parallel graft techniques. During the study
period most patients presenting with aortic aneurysms
involving the visceral aorta were treated by the hybrid
repair technique (20%) or completely endovascularly (50%).
Overall, 10 custom made branched/fenestrated grafts were
used. Conventional open surgery was performed in the
remaining 30% of cases. This series included 69 PAAAs (no
normal aorta between the origin of the aneurysm and the
lowest renal artery) and 31 TAAAs.5 Eight TAAAs extended
to the aortic arch. Seventy-three (73%) patients were
treated electively and 27 (27%) non-electively (12 ruptured
cases). Demographics and comorbidities5e8 are reported in
Table 1.
Investigational informed consent for the procedure and
study was obtained from all patients. Clinical data were
collected with the university hospital clinical information
system (Dendrite, Dendrite Clinical Systems, Ltd, Henley-on-
Thames, UK; KISIM 4.901, CISTEC AG, Zurich, Switzerland)
and updated in February 2015. Earlier data with shorter
follow up for some of these patients have been published
previously.3rate (mL/min/1.73 m ); CAD ¼ coronary artery disease; ASA
¼ American Society of Anesthesiologists; PAD ¼ peripheral artery
disease; HC/HA ¼ hostile chest/hostile abdomen (previous surgical
intervention with open chest or open abdomen); pararenal ¼
juxta- and supra-renal; thoraco-abdominal ¼ all descending aortic
aneurysm, including those extending inside the aortic arch;
CPG¼ chimney and periscope graft; ESRF¼ end stage renal function.
a W.L. Gore & Associates, Flagstaff, AZ, USA.
b Medtronic Vascular, Santa Rosa, CA, USA.
c Jotec, Hechingen, Germany.
d Cook Inc., Bloomington, IN, USA.Standardized protocol
An aortic board reviewed all cases pre-operatively to assess
CPG feasibility. Pre-operative thoraco-abdominal computed
tomographic arteriography (CTA) was performed in all pa-
tients. CTA images were analyzed with the 3mensio soft-
ware (3mensio Medical Imaging BV, Bilthoven, The
Netherlands) to assess disease extent, and aortic and
branch dimensions and angulations. The material necessary
666 F. Pecoraro et al.to construct the CPG(s) and implantation routes were based
on patient speciﬁc anatomy (Figs. 1 and 2). A 2 cm long
sealing zone in the normal vessel wall (diameter and
endoluminal morphology) was required in the aorta and its
branches. A shorter landing zone in aortic branches
(<10 mm) required special deployment techniques
(described below).
The aortic devices used are reported in Table 1. Sizing
was based on the following formula: mean aortic diameter
at landing zone þ half the diameter of each CPG used. In
patients <70 years, an additional 10% aorta oversizing was
used to anticipate future natural aortic growth. In chal-
lenging anatomies, repositionable grafts were used for more
precise deployment and possible repositioning. CPGs were
mostly constructed using a Viabahn device (WL Gore &
Associates, Flagstaff, AZ, USA). The length of the Viabahn
was chosen to extend, at least one centimeter, the CPG
beyond (above or below) the covered part of the aortic
stent graft and to leave a 1e2 cm landing zone within the
aortic branch. The Viabahn device diameter generally
included 1 mm of oversizing. In a few cases, at the beginningFigure 1. Schematic view of endovascular repair of Crawford IV aneur
arteries. Two chimneys are introduced from the left axillary artery to
teric artery (red arrow). Two periscopes are introduced from the right
arrow) renal artery. (B) The Chimney and Periscope endografts have b
aneurysm is excluded and the blood ﬂow into the reno-visceral arterieof the experience or for CPG stenosis or in the few highly
stenotic vessels, self expandable and/or balloon expandable
bare stents were used in 12 branches (5%). Overall, 224
(mean 2.24; SD 0.93; range 1e4) aortic branches were
treated with CPGs and a mean of 1.49 stent grafts/stents
was used per CPG (range 1e4; SD 0.76) (Table 2).Implantation technique
CPG procedures were performed under local (35 patients;
63 vessels) or general anesthesia (65 patients; 161 vessels).
Lidocaine 1% diluted with 8.4% sodium bicarbonate was
used for analgesia in remote access site preparation (cut
down or percutaneous). Mainly for patient comfort, anal-
gesic sedation was added to local anesthesia. Procedures
were performed in a radiology angiography suite (Artis-
zeego; Siemens AG, Forchheim, Germany) or in a hybrid
operating room (Philips Medical Systems, Inc., Shelton, CT,
USA). A bolus of 5,000 units of heparin was injected before
endovascular sheath introduction. Heparin was re-
administered to keep the activated clotting time value toysm with chimney periscope graft. (A) Access to the reno-visceral
address the celiac trunk (green arrow) and the superior mesen-
femoral artery to address the right (yellow arrow) and left (blue
een deployed. (C) After tubular aortic stent graft deployment, the
s is maintained.
Figure 2. Schematic view of endovascular repair of pararenal aneurysm with chimney periscope grafts. (A) Access to renal arteries. Two
chimneys are introduced from left axillary artery to address the renal arteries. (B) The chimneys are deployed into renal arteries. (C)
Deployment of a bifurcated aortic stent graft to exclude the aneurysm. The blood ﬂow is maintained into the renal arteries by the chimney
graft.
Risk factors for failure of chimney and periscope 667>180 seconds or >250 seconds if supra-aortic access was
used. Chimney grafts deliver antegrade ﬂow and were
generally introduced and deployed from the left axillary
artery. On the other hand, periscope grafts deliver retro-
grade blood ﬂow and were introduced transfemorally.
Following cannulation and sheath placement in the reno-
visceral branch, the Viabahn was introduced into the
target vessel, deployed, and molded with a 2 cm long an-
gioplasty balloon to achieve good anchorage. Aortic stent
grafts were deployed and pullback traction was applied to
the CPG balloon(s), to orientate the CPG(s) parallel to the
aortic axis. A simultaneous kissing ballooning completed the
procedure. Selective angiography and pressure measure-
ments inside any aortic and branch stent graft were per-
formed to exclude relevant endoleak(s) and/or signiﬁcant
pressure gradient(s). Low ﬂow Type Ia (gutters and leaks
limited to proximal neck) endoleaks,9 even in patients with
aortic rupture and coagulation disorder, were tolerated. In
the latter part of the experience (7 cases; 7%) the CPGs
were relined primarily with Wallstents (Boston Scientiﬁc
Corp., Marlborough, MA, USA) to improve visibility.10 In 22
(22%) cases a visceral debranching of one or two branches
preceded the CPGs.
Special techniques. In short reno-visceral artery landing
zones (10 mm), the CPG was deployed after the aortic
stent graft. The transfemoral lift technique was used to
construct 23/224 (10%) reno-visceral chimneys in patients
with a highly diseased aortic arch.11 Twenty-three of 224Table 2. Vessels, conﬁguration, and stents.
CPG CPG conﬁguration CPG stent typ
Total Chimney Periscope Total C
SE
RRA 80 41 39 119 1
LRA 81 48 33 120 1
SMA 38 30 8 55
CT 24 17 7 38
IMA 1 0 1 1
TOTAL 224 136 88 333 3
CPG ¼ chimney/periscope graft; BMS ¼ bare metal stent; SE ¼ self ex
artery; LRA ¼ left renal artery; SMA ¼ superior mesenteric artery; CT(10%) CPGs were constructed using the sandwich tech-
nique, by placing the CPG between two aortic stent grafts
(12), or a surgical graft and a stent graft (11) to reduce CPG
length.12 Thirteen (57%) sandwiches were constructed in
the periscope conﬁguration and 10 (43%) in the chimney
conﬁguration.
Peri-operative management
Post-operative quality controls. Duplex ultrasound (DUS)
with kidney and liver resistance index measurements was
performed immediately after the procedure. In ruptured
cases, CTA was performed immediately after the CPGe
EVAR procedure. In patients with severe chronic renal fail-
ure, contrast DUS and non-contrast CT were used during
follow up.
Treatment of endoleaks or CPGs stenosis. High ﬂow
endoleaks I/III or relevant CPG stenoses were corrected
immediately. Low ﬂow endoleaks,9 Type II endoleak and
slight stenosis not associated with a signiﬁcant pressure
gradient were managed conservatively.
Management of blood pressure. After TAAA treatment,
blood pressure was maintained between 120 and
150 mmHg for 6 weeks, to avoid spinal hypoperfusion.
Patients developing neurological symptoms while hospital-
ized were treated with Mannitol 20%, a 50 mL bolus every
2e4 hours and transferred to the ICU for blood pressure
(systolic pressure 140 mmHg; mean arterial pressure 70ees CPG dimension
overed BMS Diameter Length
SE BE
10 6 3 6.54  0.84 6.99  2.81
10 6 4 6.67  0.83 6.79  2.49
49 6 0 8.45  1.26 8.39  12.52
33 5 0 8.32  1.18 14.17  31.36
1 0 0 7 5
03 23 7 7.10  0.94 7.92  7.42
pandable stent; BE ¼ balloon expandable stent; RRA ¼ right renal
¼ celiac trunk; IMA ¼ inferior mesenteric artery.
668 F. Pecoraro et al.90 mmHg) and hematocrit (>30%) optimization. Cerebro-
spinal ﬂuid drainage (CSFD) was not used peri-operatively
and not even post-operatively in symptomatic patients
because of its debatable preventive value and because of
the serious concerns about inserting the CSFD catheter
under heparinization.
Medications. Combined antiplatelet therapy (100 mg/day
aspirin) and full therapeutic heparinization were adminis-
tered during hospitalization. Before discharge, patients
were switched to dual antiplatelet therapy or single anti-
platelet therapy combined with an oral anticoagulant for at
least 3 months. To reduce the risk of post-implantation
systemic inﬂammatory syndrome,13 vaso-plegic syn-
drome,14,15 and/or atrial ﬁbrillation16 and the consequent
low cardiac output,17 low dose steroids were administered
orally for 5 days (prednisone 20 mg/day for 2 days, pred-
nisone 10 mg/day for 2 days and prednisone 5 mg/day for 2
days).Follow up
Follow up was 6 weeks, 3 months, 6 months, and annually
thereafter; all patients were ambulatory. CTA, laboratory
testing and clinical examination were performed. Basal CT
and DUS were employed when CTA was contraindicated by
impaired renal function.18Study outcomes
Short term. The short-term outcomes were to calculate the
immediate technical success rate (procedure completed as
intended without high ﬂow Type I/III endoleak and/or CPG
occlusion), post-operative (30 day/in hospital) mortality and
morbidity (including renal, respiratory, visceral, access and
infection complications), ICU and hospital duration, CPG
patency rates, and the presence of an endoleak at 30 days.Table 3. Chimney and periscope graft related re-interventions.
Early (within 30 days) 7
CPG thrombosis 3
Treatment
CPG thrombolysis 1
PTA/stenting 2Mid-term
The mid-term outcomes were to calculate survival, CPG
patency rates, endoleak rate, maximum aneurysm size and
re-interventions during follow up. A signiﬁcant aneurysm
maximum transverse diameter (MAXTD) difference was
deﬁned as a variation of 5 mm on CTA.Endoleaks 4
Treatment
Aortic extension 3
Coiling/embolization 1
Late (after 30 days) 21
CPG thrombosis 10
Treatment
CPG extension 7
Bypass surgery 3
Endoleaks 11
Treatment
Aortic extension 6
Coiling/embolization 5
Total 28
CPG ¼ chimney periscope graft; PTA ¼ percutaneous transluminal
angioplasty.CPG failure risk factor analysis
The following variables were analyzed: (a) diagnosis of PRAA
versus TAAA; (b) elective versus non-elective treatment; (c)
1e2 CPG versus 3e4 CPG implantation; (d) CG versus PG
versus CPG conﬁguration, (e) renal versus visceral versus all
treatment; (f) aortic stent graft fabric; (g) CPG collapse
(>70% stenosis), and/or very short CPGs (<5 mm) versus
no collapse or short CPG; and (h) target vessel atheroscle-
rosis (stenosis >50%) or diameter < 4 mm versus non-
diseased vessels, which were tested for the following late
outcomes: (1) mortality at follow up; (2) aneurysm
maximum diameter reduction; (3) CPG patency; (4) re-
interventions.Statistical analysis. Means (m), range (r) and standard de-
viation (SD) were reported for parametric data; absolute
values and percentages for non-parametric data. Owing to
the inclusion of exactly 100 patients, percentages were
generally omitted when dealing with patient numbers.
Differences between groups were assessed using the t test,
and chi-square test. The risk factor multivariate analysis was
conducted with multivariate analysis of variance (MAN-
OVA). KaplaneMeier curves were used to estimate survival,
primary, and secondary patency and freedom from re-
interventions. Differences in curves were assessed with
the Breslow test. Statistical signiﬁcance was considered to
be p < .05. For KaplaneMeier curves conﬁdence interval
(CI) and standard error exceeding 10% were reported. Sta-
tistical analysis was performed using SPSS 16.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
The immediate technical success rate was 99%, as all but
one procedure could be completed as intended. In one
patient a renal artery could not be preserved. The mean
procedure time was 252 (SD 190) minutes. A signiﬁcantly
higher number of patients with multiple (>2) CPGs were
performed under general anesthesia than under local
anesthesia (2.47 vs. 1.8; p ¼ .01). Post-operative mortality
occurred in two (2%) patients who developed multiple or-
gan failure (1 rhabdomyolysis and 1 abdominal compart-
ment syndrome after ruptured PAAA). Post-operative
complications requiring re-interventions during the initial
hospitalization included an axillary hematoma (2; 2%),
bilateral lymphatic ﬁstula in the groin (1; 1%), iliac limb
occlusion (2; 2%), and mesenteric ischemia (1; 1%). More-
over, seven (7%) patients required CPG-related re-in-
terventions early for CPG thrombosis (3) and/or endoleaks
(4) (Table 3). Four subcapsular renal hematomas with no
renal functional impairment were treated conservatively.
Risk factors for failure of chimney and periscope 669No difference in peri-operative complications was observed
between acute and elective patients (5/27 [19%] vs. 10/73
[14%]; p ¼ .68). In eight patients, CPG(s) revisions were
performed as outpatient procedures.19 Neurological com-
plications (spinal cord ischemia) occurred in three cases.
These were successfully managed by pressure and hemat-
ocrit optimization and infusion of 50 mL of Mannitol 20%
every 4 hours until the symptoms disappeared.
The overall experience with a median follow up of 28
(mean 29; range 0e65; SD 17) months including 59 patients
followed > 2 years, 30 patients followed > 3 years and 16
patients followed > 4 years. Only one patient (1%) was lost
during follow up. A 14% reduction in aneurysm maximum
transverse diameter (CI 5.39e10.28; p < .001) was
observed between the pre-operative (71.76 [median 65;
range 38e185; SD 23] mm) and the last CTA (61.49 [median
56.5; range 30e162; SD 24] mm). There was a reduction of
the maximal transverse diameter in 56 (56%) patients, no
change in 40 (40%), and progression in four (4%). No stent
graft migration was observed (Fig. 3).
Post-operatively, 28 (28%) CPG related re-interventions
(including the 7 early ones mentioned above) were per-
formed at a mean interval of 11.45 (range 0e38; SD 26)
months; 25/28 (89%) were performed endovascularly and
three of 28 (11%) with open bypass procedures (Table 3).
Of the 28 re-interventions, 15 (54%) were performed for
endoleak related issues. At the latest follow up of all cases,
a Type I/III endoleak was evident in 5% of cases. Out of the
23 Type I/III endoleaks noted post-operatively, 15 were
treated (4 early and 11 late) and three sealedFigure 3. (A) Computed tomography (CT) showing abdominal aortic an
CT three dimensional reconstruction showing regular patency of renal
renal chimneys and aortic stent graft. (D) CT showing aortic aneurysmspontaneously. The remaining ﬁve Type I/III endoleaks were
low ﬂow. These remain under surveillance as long as the
aneurysm diameter remains stable (Table 3). The estimated
endoleak free survival after secondary procedures is shown
in Fig. 4.
Post-operatively, relevant CPG stenosis or thrombosis
requiring re-intervention was detected in 13 of 224 (5.8%)
branches. The mean interval to re-intervention was 2.6
(range 0e6; SD 2) months; three branches were treated
early and 10 later during follow up (Table 3). Primary
patency at 12, 24, 36, and 48 months was 94%, 94%, 93%
and 93% respectively, and secondary patency 97%, 97%,
96%, and 96% respectively (Fig. 5A). The number of CPGs
was not related to patency rates (p ¼ .10) or to CPG
conﬁguration (p ¼ .90).
Estimated freedom from re-intervention(s) at 12, 24, 36,
and 48 months was 77%, 73%, 64%, and 53% respectively.
No signiﬁcant difference in the re-intervention rate was
observed for the number of CPGs (p ¼ .35) or elective
versus non-elective patients (p ¼ .33). No difference in
renal function (glomerular ﬁltration rate) was observed
between pre-operative and follow up (54 mL/min/1.72 m2;
SD 13 vs. 56 mL/min/1.72 m2; SD 16; p ¼ .84).
Two patients developed an irreversible delayed para-
plegia at 6 and 5 weeks after Type II or Type I TAAA. In both,
new onset of atrial ﬁbrillation and systolic blood pressure
<100 mmHg were recorded.
Overall estimated patient survival at 12, 24, 36, and 48
months was 91%, 84%, 79%, and 79% respectively. Esti-
mated aneurysm related survival at 12, 24, 36, and 48eurysm maximum diameter (53 mm). (B) Aneurysm follow up with
chimneys and visceral vessels. (C) CT corresponding plain view of
sac shrinkage.
Figure 4. Freedom from Type I/III endoleaks at 12, 24, 36, and 48 months was 96%, 94%, 94%, and 94%. Standard error does not exceed
10% at 48 months (CI 53.18e59.75).
670 F. Pecoraro et al.months was 93%, 90%, 90%, and 90% (Fig. 5B). Survival was
not related to the type of aortic aneurysm treated (PRAA vs.
TAAA) (p ¼ .077) but to the type of repair (elective vs.
emergent) (p ¼ .003). One patient (4%, 1/28) died after re-
intervention (irreversible shock after an iliac artery disrup-
tion). During the follow up, 19 patients died (2 early and 17
late deaths). Of these 17 late deaths, ﬁve were directly
related to the initial CPGeaortic stent graft procedure or a
re-intervention.Figure 5. (A) Primary patency at 12, 24, 36, and 48 months was 94%
months (CI 50.58e62.83). Secondary patency at 12, 24, 36, and 48 mon
10% at 48 months (CI 60.83e64.12). No signiﬁcant differences in prim
survival at 12, 24, 36, and 48 months was 91%, 84%, 79%, and 79%. Sta
Aneurysm related survival at 12, 24, 36, and 48 months was 93%, 90%,
(CI 55.62e62.70).The risk factor multivariate analysis for CPG failure
showed a higher mortality (p ¼ .001) and re-intervention
rate (p ¼ .01) in patients treated non-electively; a higher
mortality rate in patients treated with multiple (3e4) CPGs
(p ¼ .03); a higher re-intervention rate in highly stenosed or
short CPGs (p ¼ .02); and a higher CPG occlusion (p ¼ .004)
and re-intervention rate (p ¼ .005) in stenosed or small
target vessels. There were associations with re-
interventions for multiple (3e4) CPGs (p ¼ .06); with, 94%, 93%, and 93%. Standard error does not exceed 10% at 48
ths was 97%, 97%, 96%, and 96%. Standard error does not exceed
ary and secondary patency (CI 60.24e62.94; p ¼ .17). (B) Overall
ndard error does not exceed 10% at 48 months (CI 48.86 to 57.85).
90%, and 90%. Standard error does not exceed 10% at 48 months
Table 4. Multivariate risk factors analysis.
Variables Outcomes
Mortality at FUP (n) TDmax reduction (mm) CPG patency
(occlusion; n)
Re-interventions (n)
PRAA (69) vs. TAAA (31) 13 vs. 6; p ¼ .32 7 vs. 10; p ¼ .77 9 vs. 4; p ¼ .97 21 vs. 12; p ¼ .15
Elective (73)
vs. non-elective (27)
9 vs. 10; p ¼ .001 14 vs. 6; p ¼ .62 10 vs. 3; p ¼ .52 27 vs. 6; p ¼ .01
1e2 CPG (68) vs. 3e4 CPG (32) 9 vs. 10; p ¼ .03 9 vs. 9; p ¼ .17 4 vs. 12%; p ¼ .84 13 vs. 20; p ¼ .06
CG (50) vs.
PG (28) vs. CPG (22)
5 vs. 7 vs. 7; p ¼ .06 10 vs. 9 vs. 11; p ¼ .59 3 vs. 4 vs. 6; p ¼ .95 13 vs. 11 vs. 9; p ¼ .33
Renal (58) vs.
visceral (10) vs. all (32)
11 vs. 1 vs. 7; p ¼ .72 11 vs. 9 vs. 10; p ¼ .12 9 vs. 0 vs. 4; p ¼ .41 16 vs. 4 vs. 13; p ¼ .40
Aortic stent graft
(55 vs. 27 vs. 17 vs. 1)
11 vs. 5 vs. 3 vs.
0; p ¼ .96
10 vs. 11 vs. 9 vs.
12; p ¼ .12
6 vs. 4 vs. 3 vs.
0; p ¼ .86
17 vs. 6 vs. 9 vs.
1; p ¼ .08
CPG >70% stenosis and/
or CPGs <5 mm length (29)
vs. no collapse/short CPG (71)
13 vs. 6; p ¼ .30 8 vs. 10; p ¼ .76 4 vs. 9; p ¼ .06 25 vs. 8; p ¼ .02
Target vessel stenosis >50%
or <4 mm diameter (78) vs.
not diseased vessels (22)
14 vs. 5; p ¼ .65 15 vs. 6; p ¼ .09 8 vs. 5; p ¼ .04 19 vs. 16; p ¼ .05
n ¼ absolute number; PAAA ¼ pararenal aortic aneurysm; TAAA ¼ thoraco-abdominal aortic aneurysm; CPG ¼ chimney periscope graft;
CG ¼ chimney graft; PG ¼ periscope graft; FUP ¼ follow up; TDmax ¼ maximal transverse diameter.
Signiﬁcant values are represented in bold.
Risk factors for failure of chimney and periscope 671mortality for combined CPGs (p ¼ .06); and with CPG oc-
clusion for highly stenosed or short CPGs (p ¼ .006)
(Table 4).DISCUSSION
Studies reporting the mid- and longer-term outcomes of
chimney and/or periscope grafts used in reno-visceral ves-
sels are rare and identiﬁcation of risk factors for chimney
and/or periscope graft failure are lacking.20 As reported
recently by the multicenter PERICLES registry, the results at
17.1 months from 517 patients treated by CPGs were
similar to those of F/BEVAR. However, in this registry
different devices (bare metal, covered, self expandable, or
balloon expandable) have been used in reno-visceral vessels
and no risk factor analysis for CPG failure was performed.21
Based on the VORTEC experience using the Viabahn for
sutureless anastomoses in reno-visceral vessels,22e24 it was
felt that felt that the Viabahn device would be ideal for CPG
construction and therefore it was used exclusively for the
parallel graft(s) in reno-visceral vessels. The intuition was
conﬁrmed in the actual series of 100 patients followed for a
mean period of 28 months by absence of material failure
and the high primary patency rate (93%) in the 16 patients
followed >4 years. Post-operatively, CPG occlusion was
observed in only 5.8% branches; the risk factors were CPG
collapse and/or too short CPGs, target vessel atheroscle-
rosis or a diameter <4 mm. With regard to the aortic stent
graft there was no difference in outcome, maybe because of
the relatively small samples. Few experimental and clinical
data support the use of one device (aortic stent graft or
branch stent graft) over another,3,9,18,25 and long-term re-
sults with different types of CPG devices (self expandable or
balloon expandable) are needed.26 The Viabahn is preferred
for CPG construction because of its low proﬁle, ﬂexibility,and heparin coating. The excellent results, also in patients
with long-term follow up, support this choice. In addition,
the Viabahn X-ray visibility may increase with primary
Wallstent relining.10 This tool was employed increasingly in
the later procedures, especially in cases of multiple CPGs.
Finally, the 4 year cumulative patency rate of aortic
branches preserved with CPGs is equivalent to those re-
ported after B/FEVAR treatment for similar aortic pathol-
ogies (96% vs. 88.6%).27e29 In this study, to ﬁt the patient
anatomy, different stent graft manufacturers were com-
bined and used concurrently with no differences. This
approach has been used with caution, and no drawbacks
have been observed to date.
Endoleaks are regarded as a major concern9 and repre-
sent a potential cause of aneurysm rupture.26,30 The policy
to perform very sensitive CTA (arterial and venous phases)
early post-operatively might explain the 23% endoleak
incidence. However, this high rate must be tempered by the
lack of persistence or clinical adverse consequences if
endoleaks are addressed appropriately. When the endoleak
did not seal spontaneously, it was eliminated by coil-
embolization or endograft extension, which showed dura-
ble effects over time. Persisting low ﬂow Type I endoleaks
did not result in aneurysm enlargement. Overall and despite
these endoleaks, aneurysm diameter remained stable or
decreased in 96% of patients, which compares favorably
with the ﬁndings described after FEVAR (92e97%).29,31,32
Moreover, when compared with data from Schanzer
et al.,33 sac enlargement was less in the current series. It
can be argued that this enlargement was related not only to
a lower endoleak incidence (32 vs. 23%), but also to
aggressive endoleak treatment based on adherence to a
stricter follow up protocol.
Clinical outcomes of the mid- and longer-term experience
of parallel graft techniques are consistent with 2% peri-
672 F. Pecoraro et al.operative mortality and 79% survival rate at 4 years’ follow
up. Although controversies exist on CPG outcomes,34 the
results compare favorably with those of both B/FEVAR and/
or open surgery. The reported peri-operative mortality rate
after B/FEVAR ranges between 2.1% for juxtarenal AAA and
7.8% for TAAA;29,35 the 5 year survival rate ranges between
91% for juxtarenal and 67% for TAAA.29,36 These survival
outcomes of both CPGs and F/BEVAR compare favorably
with randomized control trials reporting on infrarenal AAA
treatment, such as the EVAR37 and OVER38 trial using the
older generation devices. Also the more recent cardiovas-
cular medical support can play a role in survival outcome.39
General anesthesia was employed more frequently in
multiple CPGs and local anesthesia for less complex pro-
cedures. Patients treated for TAAAs required signiﬁcantly
longer ICU stays and showed less aneurysm shrinkage than
patients treated for PRAAs. Moreover, in this group of pa-
tients, CPG outcomes seemed far better than those of
similar lesions treated by open aortic surgery.40 During
follow up, patient survival after non-elective procedures
and procedures requiring more than two CPGs was worse
than after elective procedures with one or two CPGs. Pa-
tients requiring elective treatment with only one or two
CPGs clearly had the best outcomes. However, the higher
risk and challenging nature of patients requiring more
complex procedures would seem to justify the CPG tech-
niques in these patients as well.
This study has some limitations. First, there is no
contemporary (institutional) clinical comparison with FEVAR
or open repair. The main reason for this is that the actual
study focus was on outcomes and risk factors for CPG
complications, especially when the Viabahn branch grafts
were used. As the Viabahn device is generally not used in
FEVAR procedures, comparisons might have yielded
confusing results of limited value. A second limitation of the
study is that it included the learning curve(s) with different
skills and techniques developed during experience with
CPGs. A third limitation is that the study included a mixed
group of different aortic lesions and clinical conditions
(elective and emergent). In fact, as experience progressed,
the techniques were adapted and developed so the CPG
option could be offered to most patients with AAAs and/or
TAAAs involving reno-visceral branch arteries. Because of
this, and because major differences in constructing CPGs
were not identiﬁed in these different anatomical and clin-
ical circumstances, the group as a whole was reviewed to
obtain sufﬁcient numbers of patients to enable the authors
to identify risk factors for CPG complications. Nevertheless,
the results may not apply to CPG grafts constructed with
different components or conﬁgurations. However the
PERICLES registry results suggests that this may not be a
limitation.21
In conclusion, this experience in 100 patients treated
with self expanding CPGs shows promising and durable mid-
and longer-term term results (>4 years). Diseased native
vessels, highly stenosed, or short CPGs and multiple (3e4)
CPGs were signiﬁcant risk factors for CPG failure. Non-
elective CPG and multiple (3e4) CPGs were signiﬁcant riskfactors for death. Although the data suggest that the par-
allel graft methods for reno-vascular revascularization with
complex AAAs may be equivalent to open surgery or FEVAR,
more widespread experience and direct comparisons will be
required to conﬁrm this. The potential advantages of CPG
techniques (off the shelf, versatility, generally immediate
availability and low-proﬁle devices) are obvious; however,
the best indications for CPGs remain to be clariﬁed. How-
ever, even at present, the wider use of such parallel grafting
techniques, using the Viabahn, seems to be justiﬁed in sit-
uations in which F/BEVAR is not available and patients are
at high risk for open surgical repair.
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